S 1818 · in committee · major
Prescription Drug Price Relief Act of 2025
- healthcare
What this bill does
- The government must review brand-name drug prices yearly and void exclusive rights if prices are found excessive.
- Drug manufacturers and patients needing affordable medications are affected by this pricing review process.
- HHS creates a public database of pricing decisions and allows generic alternatives to be made at lower costs.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would annual government price reviews affect the timeline for bringing new medications to market versus lowering costs for patients?
- 02
What metrics would determine whether a drug's price is excessive, and who decides if those standards are appropriate?
- 03
If manufacturers lose exclusive rights to high-priced drugs, how might that change their investment in developing treatments for rare diseases?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · I-VT
Bernard Sanders
Citizen cosponsors
0
In Congress
7/ 100
Senators cosponsoring
Introduced 2025-05-20
Joining the bill
Legislative timeline
2025-05-20 · senate · IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2025-05-20 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.